

Breast Cancer[®]

U P D A T E

An Audio Review Journal for Nurses

Management of Breast Cancer in the Adjuvant and Metastatic Settings

EDITOR

Neil Love, MD

FACULTY

Dianne D Chapman, ND, RN, ANP

Hope S Rugo, MD

Mark D Pegram, MD

Harold J Burstein, MD, PhD

Stephen E Jones, MD



A Continuing Nursing Education Audio Series

STATEMENT OF NEED/TARGET AUDIENCE

Medical oncology, particularly breast cancer, is one of the most rapidly advancing and developing fields of medicine. The constant emergence of new systemic agents, new indications for existing systemic agents, novel therapies, clinical trials and research findings demands that oncology nurses remain dedicated to continuing education in order to offer their patients the best care possible. This program provides registered nurses access to the most up-to-date research developments in breast cancer and the opinions of oncology nurses and clinical investigators with experience and expertise in the field. This information can be effectively translated into everyday patient management decisions.

PURPOSE STATEMENT

To present the most current research developments in breast cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of breast cancer.

EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF *BREAST CANCER UPDATE FOR NURSES*

- Discuss the clinical implications of emerging clinical trial data in breast cancer treatment and how to incorporate these data into management strategies in the adjuvant, neoadjuvant and metastatic settings.
- Discuss the selection and sequencing of endocrine therapy in the adjuvant and metastatic settings.
- Describe the risks and benefits of chemotherapeutic agents and regimens in the adjuvant and metastatic settings.
- Describe the computerized risk models and genetic markers to determine prognostic information on the quantitative risk of breast cancer relapse.
- Explain the risks and benefits of incorporating biologic agents in the adjuvant and metastatic settings.

ACCREDITATION STATEMENTS

This educational activity for 3.25 contact hours (60-minute contact hour) is provided by Research To Practice during the period of March 2007 through March 2008.

Research To Practice is an approved provider of continuing nursing education by the New Jersey State Nurses Association, Provider Number P215-01/07-10. NJSNA is accredited by the ANCC Commission on Accreditation. Provider Approval is valid through January 31, 2010.

HOW TO USE THIS CNE ACTIVITY

This is an audio CNE program. This book contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Evaluation Form. The corresponding website BreastCancerUpdate.com/Nurses also includes links to relevant abstracts and full-text articles.

The Post-test and Evaluation Form may be completed in this book and either mailed to Research To Practice, 2 South Biscayne Blvd, Suite 3600, Miami, FL 33131 or faxed to (305) 377-9998. They may also be completed online. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 70 percent or better and a completed Evaluation Form. Your statement of credit will be mailed to you within three weeks or may be printed online.

This program is supported by education grants from Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc and Sanofi-Aventis.

If you would like to discontinue your complimentary subscription to *Breast Cancer Update for Nurses*, please email us at Info@ResearchToPractice.com, or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

Breast Cancer®

U P D A T E

FACULTY AFFILIATIONS



Dianne D Chapman, ND, RN, ANP

Nurse Practitioner, Comprehensive Breast Center/RISC Program
Division of Hematology and Oncology
Rush University Medical Center
Chicago, Illinois



Harold J Burstein, MD, PhD

Assistant Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts



Hope S Rugo, MD

Clinical Professor of Medicine
Carol Franc Buck Breast Care Center
Co-director, Breast Oncology
Clinical Trials Program
University of California, San Francisco
Comprehensive Cancer Center
San Francisco, California



Stephen E Jones, MD

Director, Breast Cancer Research
Charles A Sammons Cancer Center
Baylor University Medical Center
Dallas, Texas
Chair, US Oncology
Breast Cancer Research
Medical Director
US Oncology Research
Houston, Texas



Mark D Pegram, MD

Associate Professor of Medicine
David Geffen School of Medicine at UCLA
Director, Women's Cancer Program
UCLA/Jonsson Comprehensive
Cancer Center
Los Angeles, California

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and external, independent reviewers for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Lisa Aiello-Laws, RN, MSN, APN,C, AOCNS, John H Brebner, Regina Seery Cunningham, PhD, RN, AOCN, Richard Kaderman, PhD, Neil Love, MD, Paula Mateo, RN, BA, Douglas Paley, Margaret Peng, Lillian Sklaver Poltorack, PharmD, Ginelle Suarez, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Chapman — Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Genomic Health Inc, Genentech BioOncology. **Dr Rugo** — Contracted Research: Genentech BioOncology. **Dr Pegram** — Consulting Fees: Genentech BioOncology, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Genentech BioOncology, Sanofi-Aventis. **Dr Burstein** — Speakers Bureau: Amgen Inc, Genentech BioOncology. **Dr Jones** — Consulting Fees: Genentech BioOncology, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Sanofi-Aventis.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Breast Cancer Update for Nurses — Issue 1, 2007**QUESTIONS (PLEASE CIRCLE ANSWER):**

1. Patients with node-negative, ER-positive tumors and a high recurrence score, according to the *Oncotype DX™* assay, have been shown to benefit from adjuvant _____.
 - a. Fulvestrant
 - b. Anastrozole
 - c. Chemotherapy
 - d. All of the above
2. Aromatase inhibitors are efficacious in _____ patients with early, ER-positive disease.
 - a. Premenopausal
 - b. Postmenopausal
 - c. Both a and b
3. Clinical trials have reported that adjuvant trastuzumab administered to a patient with HER2-positive breast cancer reduces her relative risk of recurrence by approximately _____.
 - a. 10 percent
 - b. 20 percent
 - c. 30 percent
 - d. 40 percent
 - e. 50 percent
4. In the BCIRG 006 trial, the combination of docetaxel, carboplatin and trastuzumab in the adjuvant setting reduced the risk of recurrence without increasing the risk of congestive heart failure.
 - a. True
 - b. False
5. Which of the following is associated with the use of *nab* paclitaxel?
 - a. Fewer allergic reactions
 - b. Premedication
 - c. Shorter infusion times
 - d. Both a and c
6. The standard of care in adjuvant endocrine therapy for premenopausal patients with early, ER-positive breast cancer is _____.
 - a. Exemestane
 - b. Anastrozole
 - c. Letrozole
 - d. Tamoxifen
7. In adjuvant clinical trials, a survival advantage has been demonstrated for patients switched from tamoxifen to an aromatase inhibitor versus those patients who remained on tamoxifen.
 - a. True
 - b. False
8. The ECOG-E2100 trial, which randomly assigned patients with metastatic breast cancer to paclitaxel with or without bevacizumab, demonstrated a significant reduction in the risk of progression for which arm of the trial?
 - a. Paclitaxel alone
 - b. Paclitaxel with bevacizumab
9. Bevacizumab is an anti-angiogenic agent that targets which of the following?
 - a. Estrogen receptor
 - b. Progesterone receptor
 - c. VEGF
 - d. HER2
10. In the ongoing RIBBON trials 1 and 2, _____ is combined with a variety of chemotherapy agents as first- or second-line therapy, respectively, for metastatic breast cancer.
 - a. Trastuzumab
 - b. Bevacizumab
 - c. Exemestane
 - d. Letrozole
11. The rationale for starting fulvestrant treatment with a loading dose is to reach a steady state more quickly to increase its effectiveness.
 - a. True
 - b. False
12. Which endocrine therapy is administered by injection?
 - a. Tamoxifen
 - b. Anastrozole
 - c. Exemestane
 - d. Fulvestrant
13. Trastuzumab monotherapy has proved to be _____ in patients with metastatic, HER2-positive breast cancer.
 - a. Effective
 - b. Ineffective

EVALUATION FORM

Breast Cancer Update for Nurses — Issue 1, 2007

Research To Practice respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this Evaluation Form. A statement of credit will be issued only upon receipt of a completed Evaluation Form and a completed Post-test with a score of 70 percent or better.

Please answer the following questions by circling the appropriate rating:

5 =
Outstanding

4 =
Good

3 =
Satisfactory

2 =
Fair

1 =
Poor

EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED GOAL

- To present the most current research developments in breast cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of breast cancer. 5 4 3 2 1

EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES

Upon completion of this activity, participants should be better able to:

- Discuss the clinical implications of emerging clinical trial data in breast cancer treatment and how to incorporate these data into management strategies in the adjuvant, neoadjuvant and metastatic settings. 5 4 3 2 1
- Discuss the selection and sequencing of endocrine therapy in the adjuvant and metastatic settings. 5 4 3 2 1
- Describe the risks and benefits of chemotherapeutic agents and regimens in the adjuvant and metastatic settings. 5 4 3 2 1
- Describe the computerized risk models and genetic markers to determine prognostic information on the quantitative risk of breast cancer relapse. 5 4 3 2 1
- Explain the risks and benefits of incorporating biologic agents in the adjuvant and metastatic settings. 5 4 3 2 1

EFFECTIVENESS OF THE INDIVIDUAL FACULTY MEMBERS

Faculty	Knowledge of subject matter	Effectiveness as an educator
Dianne D Chapman, ND, RN, ANP	5 4 3 2 1	5 4 3 2 1
Hope S Rugo, MD	5 4 3 2 1	5 4 3 2 1
Mark D Pegram, MD	5 4 3 2 1	5 4 3 2 1
Harold J Burstein, MD, PhD	5 4 3 2 1	5 4 3 2 1
Stephen E Jones, MD	5 4 3 2 1	5 4 3 2 1

OVERALL EFFECTIVENESS OF THE ACTIVITY

- Will assist me in improving patient care. 5 4 3 2 1
- Fulfilled my educational needs. 5 4 3 2 1
- Avoided commercial bias or influence. 5 4 3 2 1

IMPACT OF THE ACTIVITY

The information presented (check all that apply):

- Reinforced my current practice/treatment habits.
- Enhanced my current knowledge base.

EVALUATION FORM

Breast Cancer Update for Nurses — Issue 1, 2007

IMPACT OF THE ACTIVITY (CONTINUED)

Will the information presented cause you to make any changes in your practice?

- Yes No

If yes, please describe any change(s) you plan to make in your practice as a result of this activity:

If yes, how committed are you to making these changes?

(5 = very committed; 1 = not at all committed) 5 4 3 2 1

FUTURE ACTIVITIES

Do you feel future activities on this subject matter are necessary and/or important to your practice?

- Yes No

Please list any other topics that would be of interest to you for future educational activities:

Additional comments about this activity:

FOLLOW-UP

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:

- Yes, I am willing to participate in a follow-up survey. No, I am not willing to participate in a follow-up survey.

REQUEST FOR CREDIT — please print clearly

Name: Degree: Organization: Specialty: Address: City, State, Zip: Telephone: Fax: Email: Signature: Date:

Which of the following audio formats of this program did you use?

- Audio CDs Downloaded MP3s from website

To obtain credit, complete the Post-test and Evaluation Form and either mail to Research To Practice, 2 South Biscayne Blvd, Suite 3600, Miami, FL 33131, fax to (305) 377-9998 or complete both online. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 70 percent or better and a completed Evaluation Form. Your statement of credit will be mailed to you within three weeks or may be printed online.

Breast Cancer®

U P D A T E

Editor/CME Director	Neil Love, MD
Managing Editor	Kathryn Ault Ziel, PhD
Scientific Director	Richard Kaderman, PhD
Writers	Lillian Sklaver Poltorack, PharmD Douglas Paley
Continuing Education Administrator for Nursing	Sally Bogert, RNC, WHCNP
Content Validation	Margaret Peng John H Brebner Ginelle Suarez Erin Wall
Director, Creative and Copy Editing	Aura Herrmann
Creative Manager	Fernando Rendina
Graphic Designers	Jason Cunnius Tamara Dabney Shantia Daniel Elisa Stambouli
Senior Production Editor	Alexis Oneca
Traffic Manager	Tere Sosa
Copy Editors	Dave Amber Rosemary Hulce Kirsten Miller Pat Morrissey/Havlin Carol Peschke Susan Petrone
Audio Production	Frank Cesarano
Technical Services	Arly Ledezma
Web Master	John Ribeiro
Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: NLove@ResearchToPractice.com
For CE Information	Email: CME@ResearchToPractice.com

Copyright © 2007 Research To Practice. All rights reserved.

The compact discs, internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their

own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Breast Cancer[®]

U P D A T E

Copyright © 2007 Research To Practice.

This program is supported by education grants from
Abraxis Oncology, AstraZeneca Pharmaceuticals LP,
Genentech BioOncology, Genomic Health Inc and Sanofi-Aventis.



Sponsored by Research To Practice.

Last review date: March 2007

Release date: March 2007

Expiration date: March 2008

Contact hours: 3.25 (60 minute)